Development and validation of a nomogram incorporating gene expression profiling and clinical factors for accurate prediction of metastasis in patients with cutaneous melanoma following Mohs micrographic surgery - 15/03/22
, Kyle R. Covington, PhD b, Hillary G. Caruso, PhD b, Ann P. Quick, PhD b, Olga Zolochevska, PhD b, Gregory M. Bricca, MD c, Michael Campoli, MD, PhD d, James R. DeBloom, MD e, Michael J. Fazio, MD f, Bradley N. Greenhaw, MD g, E. Brent Kirkland, MD h, Mac L. Machan, MD i, David G. Brodland, MD j, John A. Zitelli, MD jAbstract |
Background |
There is a need to improve prognostic accuracy for patients with cutaneous melanoma. A 31-gene expression profile (31-GEP) test uses the molecular biology of primary tumors to identify individual patient metastatic risk.
Objective |
Develop a nomogram incorporating 31-GEP with relevant clinical factors to improve prognostic accuracy.
Methods |
In an IRB-approved study, 1124 patients from 9 Mohs micrographic surgery centers were prospectively enrolled, treated with Mohs micrographic surgery, and underwent 31-GEP testing. Data from 684 of those patients with at least 1-year follow-up or a metastatic event were included in nomogram development to predict metastatic risk.
Results |
Logistic regression modeling of 31-GEP results and T stage provided the simplest nomogram with the lowest Bayesian information criteria score. Validation in an archival cohort (n = 901) demonstrated a significant linear correlation between observed and nomogram-predicted risk of metastasis. The resulting nomogram more accurately predicts the risk for cutaneous melanoma metastasis than T stage or 31-GEP alone.
Limitations |
The patient population is representative of Mohs micrographic surgery centers. Sentinel lymph node biopsy was not performed for most patients and could not be used in the nomogram.
Conclusions |
Integration of 31-GEP and T stage can gain clinically useful prognostic information from data obtained noninvasively.
Le texte complet de cet article est disponible en PDF.Key words : 31-GEP, gene expression profiling, melanoma, metastasis, Mohs micrographic surgery, molecular classification, nomogram, prognosis, recurrence, survival
Abbreviations used : 31-GEP, AJCC, BT, CM, DMFS, HR, MMS, MSS, SLNB
Plan
| Funding sources: A statistician was provided by Castle Biosciences, Inc. The IRB was funded by the Skin Cancer Trust for Independent Research and Education, a 501c3 organization managed by Drs Zitelli and Brodland. |
|
| IRB approval status: The study was approved by the Western International Review Board. |
Vol 86 - N° 4
P. 846-853 - avril 2022 Retour au numéro
Article précédent
- Real-world comorbidities of atopic dermatitis in the US adult ambulatory population
- Youkyung S. Roh, Amy H. Huang, Nishadh Sutaria, Una Choi, Shannon Wongvibulsin, Justin Choi, Zachary A. Bordeaux, Varsha Parthasarathy, Junwen Deng, Deepa P. Patel, Joseph K. Canner, Anna L. Grossberg, Shawn G. Kwatra
- Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial
- Tessa Niemeyer–van der Kolk, Thomas P. Buters, Lara Krouwels, Jiry Boltjes, Marieke L. de Kam, Hein van der Wall, Dirk C.J.G. van Alewijk, Ellen H.A. van den Munckhof, Martin J. Becker, Gary Feiss, Edwin F. Florencia, Errol P. Prens, Matthijs Moerland, Jacobus Burggraaf, Robert Rissmann, Martijn B.A. van Doorn
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?